These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29936782)

  • 1. 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1577-1583. PubMed ID: 29936782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3375-3381. PubMed ID: 30583343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(16):7123-7. PubMed ID: 26514500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
    Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
    Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    Murray NP; Aedo S; Reyes E; Orellana N; Fuentealba C; Jacob O
    BJU Int; 2016 Oct; 118(4):556-62. PubMed ID: 26507242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Dueñas R
    Arch Esp Urol; 2014 Oct; 67(8):684-91. PubMed ID: 25306986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
    Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the Presence of Primary Circulating Prostate Cells Imply the Presence of Agressive Prostate Cancer with Early Biochemical Failure: a Comparison with the Walz Nomogram.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Orellana S; Jacob O
    Asian Pac J Cancer Prev; 2016; 17(7):3089-93. PubMed ID: 27509934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Bádinez L; Olivares R; Porcell J; Dueñas R
    ScientificWorldJournal; 2013; 2013():762064. PubMed ID: 23653529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and characteristics of primary circulating prostate cells; association with micrometastasis and implications for surgical treatment of men with prostate cancer.
    Murray NP; Reyes E; Badínez L; Orellana N; Dueñas R; Fuentealba C
    Arch Esp Urol; 2010 Jun; 63(5):345-53. PubMed ID: 20587839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
    Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
    Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
    Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
    Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head to Head Comparison of the Chun Nomogram, Percentage Free PSA and Primary Circulating Prostate Cells to Predict the Presence of Prostate Cancer at Repeat Biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2016; 17(6):2941-6. PubMed ID: 27356715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in Chile.
    Murray NP; Reyes E; Fuentealba C; Jacob O; Orellana N
    Asian Pac J Cancer Prev; 2014; 15(21):9335-9. PubMed ID: 25422221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
    Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
    Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.